We are live on ! Find out more
CRVS icon

Corvus Pharmaceuticals
CRVS

164 hedge funds and large institutions have $1.02B invested in Corvus Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 68 funds opening new positions, 55 increasing their positions, 30 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more funds holding in top 10

Funds holding in top 10: 1 → 5 (+4)

185% more capital invested

Capital invested by funds: $359M → $1.02B (+$665M)

172% more first-time investments, than exits

New positions opened: 68 | Existing positions closed: 25

158% more call options, than puts

Call options by funds: $21M | Put options by funds: $8.14M

83% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 30

32% more funds holding

Funds holding: 124 → 164 (+40)

20.94% more ownership

Funds ownership: 62.51% → 83.45% (+21%)

Holders
164
Holders Change
+40
Holders Change %
+32.26%
% of All Funds
2.02%
Holding in Top 10
5
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+400%
% of All Funds
0.06%
New
68
Increased
55
Reduced
30
Closed
25
Calls
$21M
Puts
$8.14M
Net Calls
+$12.9M
Net Calls Change
+$13.2M

Top Buyers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$46M
2
DTC
Deep Track Capital
Connecticut
+$39.8M
3
CC
Commodore Capital
New York
+$36M
4
Wellington Management Group
Wellington Management Group
Massachusetts
+$32M
5
B
Braidwell
Connecticut
+$28M

Top Sellers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$22.1M
2
Morgan Stanley
Morgan Stanley
New York
-$17.1M
3
MB
MPM BioImpact
Massachusetts
-$17.1M
4
ACM
ADAR1 Capital Management
Texas
-$6.03M
5
Jane Street
Jane Street
New York
-$5.33M
Name Holding Trade Value Shares
Change 		Change in
Stake
Tudor Investment Corp
101
Tudor Investment Corp
Connecticut
$402K +$439K +27,494 New
CUAMC
102
China Universal Asset Management Company
China
$397K +$143K +8,986 +49%
BCM
103
Bridgeway Capital Management
Texas
$391K – – –
WG
104
Winton Group
United Kingdom
$389K +$425K +26,620 New
IIM
105
INTECH Investment Management
Florida
$342K -$201K -12,592 -35%
Wells Fargo
106
Wells Fargo
California
$342K -$626K -39,254 -63%
QCM
107
Quantinno Capital Management
New York
$336K +$367K +22,982 New
TBWA
108
Three Bridge Wealth Advisors
California
$327K – – –
BNP Paribas Financial Markets
109
BNP Paribas Financial Markets
France
$312K +$235K +14,747 +225%
SAM
110
Simplify Asset Management
Nevada
$296K +$323K +20,242 New
BGM
111
Burkehill Global Management
New York
$293K +$319K +20,000 New
Corient Private Wealth
112
Corient Private Wealth
Florida
$290K +$316K +19,797 New
New York State Common Retirement Fund
113
New York State Common Retirement Fund
New York
$265K -$11.2K -700 -4%
PFSRSONJ
114
Police & Firemen's Retirement System of New Jersey
New Jersey
$264K +$39.7K +2,486 +16%
SFS
115
Sowell Financial Services
Arkansas
$219K -$31.9K -2,000 -12%
Citigroup
116
Citigroup
New York
$217K -$207 -13 -0.1%
EFM
117
E Fund Management
China
$207K +$226K +14,156 New
AC
118
AXQ Capital
New Jersey
$201K +$18K +1,131 +9%
ProShare Advisors
119
ProShare Advisors
Maryland
$191K -$11.8K -739 -5%
SWM
120
Shelton Wealth Management
Texas
$179K -$53.8K -3,370 -22%
VF
121
Virtu Financial
New York
$175K +$191K +11,951 New
Prudential Financial
122
Prudential Financial
New Jersey
$171K +$186K +11,675 New
OIA
123
OneDigital Investment Advisors
Kansas
$157K +$11.4K +716 +7%
DS
124
DRW Securities
Illinois
$155K -$204K -12,800 -55%
TC
125
Truvestments Capital
Florida
$150K – – –
3 4
5
6 7

CRVS Hedge Fund Activity: Q1 2026 in Review

164 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q1 2026, worth a combined $1.02B — up 185% from $359M a quarter earlier.

Buyers outnumbered sellers: 68 funds opened new CRVS positions and 25 closed out — a net gain of 43 holders — while 55 added to existing stakes and 30 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $46M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $22.1M sold.

  • 164 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q1 2026, up from 124 in Q4 2025.
  • Funds reported $1.02B of Corvus Pharmaceuticals stock for Q1 2026, up 185% quarter-over-quarter.
  • 68 funds opened new Corvus Pharmaceuticals positions in Q1 2026 and 25 closed out, a net change of +43 holders.
  • The largest Corvus Pharmaceuticals buyer in Q1 2026 was T. Rowe Price Associates, an estimated $46M added.
  • The largest Corvus Pharmaceuticals seller in Q1 2026 was Point72 Asset Management, an estimated $22.1M sold.

Based on aggregated 13F filings for Q1 2026.